- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | FDA grants three priority vouchers to psychedelics | ||
| Fr | FDA declines to approve AbbVie's Botox follow-up | ||
| Fr | FDA clears first genetic hearing loss gene therapy | ||
| Do | Trump's DOJ reschedules medicinal marijuana, increasing access | ||
| Do | Ray's upscaled Series B, and other biofinancings | ||
| Do | UK Biobank patient data placed on sale in China | ||
| Do | Novo says oral semaglutide works in diabetic kids | ||
| Do | UK Biobank patient data stolen and placed on sale in China | ||
| Do | UK Biobank patient data hacked and placed on sale in China | ||
| Do | Swiss franc strength puts Roche's results in a poor light | ||
| Do | Sanofi welcomes incoming CEO with sales lift | ||
| Do | AbbVie makes record investment in North Carolina plant | ||
| Mi | MSD cuts $1bn AI tool deal with Google Cloud | ||
| Mi | Neurology, biomanufacturing start-ups bag UK AI funding | ||
| Mi | Neurology, biomanufacturing startups bag UK AI funding | ||
| Mi | FDA delays decision on Sanofi's subcutaneous Sarclisa | ||
| Mi | New data build case for Roche's oral BTK drug for MS | ||
| Mi | Pivotal trial of Moderna's H5N1 bird flu jab gets underway | ||
| Mi | Medicare obesity drug pilot extended after insurer pushback | ||
| Di | Novo Nordisk preps filings for sickle cell drug etavopivat | ||
| Di | MSD, Eisai report setback in first-line kidney cancer trial | ||
| Di | Jazz Pharma and Lilly cancer drugs cleared for use by NHS | ||
| Di | FDA kicks off review of Roche's Gazyva for wider lupus use | ||
| Di | Italy leads the way on child genetic disease diagnosis | ||
| Mo | Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.